tracken
Wave Life Sciences Ltd. Aktie News
Neutral
24/7 Wall Street
●
5 Tage alt
In the past week or so, secondary offerings from biotechs Immunovant Inc. (NASDAQ: IMVT), Kymera Therapeutics Inc.
Positiv
Forbes
●
7 Tage alt
A surge of 147% in a single session is an unusual occurrence in biotech — and nearly unprecedented for a company that has spent years trading discreetly under the radar. However, that is precisely what transpired with Wave Life Sciences (NASDAQ:WVE), the RNA-focused drug developer that astonished Wall Street with data so unexpectedly robust that it reshaped the company's future in just a few ho...
Positiv
MarketBeat
●
12 Tage alt
The golden cross is a highly accurate and bullish technical signal that investors can use to find stocks that can make good momentum trades. A golden cross pattern forms when a stock's 50-day moving average crosses above its 200-day moving average.
Neutral
GlobeNewsWire
●
13 Tage alt
CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), announced today the pricing of its previously announced underwritten public offering of 15,789,475 of its ordinary shares at a price to the public of...
Positiv
The Motley Fool
●
13 Tage alt
It wasn't hard to be optimistic about the biotech's future, given its excellent news from the lab on Monday. Prognosticators fell over themselves publishing bullish new takes on the company the following day.
Positiv
The Motley Fool
●
14 Tage alt
The biotech's investigational weight loss drug did very well in a clinical trial. This is a white-hot segment of the pharmaceutical market, so it's little wonder investors subsequently pounced on the stock.
Neutral
GlobeNewsWire
●
14 Tage alt
CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), announced today that it has commenced an underwritten public offering of $250 million in aggregate of its ordinary shares, and, to certain investors ...
Neutral
Seeking Alpha
●
14 Tage alt
Wave Life Sciences Ltd. (WVE) Discusses Positive Interim Data from INLIGHT Trial of WVE-007 for Obesity Transcript
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
